This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and / or for which no standard treatment exists that has been shown to prolong survival. See study details page. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. See the table below for open treatment arms.

https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/pediatric-match#1

For more information: Cincinnati Children’s Division of Hematology / Oncology | Phone: 513-636-2799 | Emailcancer@cchmc.org

 

TARGET

STUDY / ID

AGENT

KEY WORDS

DATE MODIFIED

STATUS

NA

SC

Gilotrif® (afatinib)

Screening Protocol

11/5/2018

OPEN

Pan-TRK inhibitor

A

LOXO-101 (larotrectinib)

NTRK Fusions

4/15/2019

OPEN

FGFR inhibitor

B

JNJ-42756493 (erdafitinib)

FGFR alterations

4/02/2019

OPEN

EZH2 inhibitor

C

tazemetostat

Alterations in EZH2 or members of the SWI/SNF complex

5/13/2019

OPEN

P13K/mTOR inhibitor

D

LY3023414

Solid tumors

5/21/2018

OPEN

MEK inhibitor

E

selumetinib (AZD6244)

TActivating MAPK pathway mutations

2/01/2019

OPEN

ALK inhibitor

F

ensartinib (x-396)

ALK or ROS1 genomic alterations

2/11/2019

OPEN

BRAF inhibitor

G

vemurafenib

BRAF V600 mutations

1/14/2019

OPEN

PARP inhibitor

H

olaparib

Defects in DNA damage repair genes

11/19/2018

OPEN

CDK4 or 6 inhibitor

I

palbociclib

Activating Alterations in Cell Cycle Genes

7/9/2018

OPEN

ERK1/2 inhibitor  J  BVD-523FB (ulixertinib)  Activating MAPK pathway mutations  10/1/2018  OPEN